Andrzej Lisowski

Andrzej Lisowski

Auto-generated profile, based on publicly available information

Andrzej Lisowski

Institute of Animal Breeding and Biodiversity Conservation University of Life Sciences Lublin Poland

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 July 2020 in Journal of Veterinary Pharmacology and Therapeutics
Verified
Journal Article
Closed access
PDF file
ISIrene Sartini
Irene Sartini
BŁBEATA ŁEBKOWSKA-WIERUSZEWSKA
BEATA ŁEBKOWSKA-WIERUSZEWSKA
ALAndrzej Lisowski
Andrzej Lisowski
APAmnart Poapolathep
Amnart Poapolathep
BCBarbara Cuniberti
Barbara Cuniberti
MVMario Giorgi Dip Scienze Veterinarie
Mario Giorgi Dip Scienze Veterinarie

11 September 2014
Verified
Book Chapter
Closed access
PDF file
ALAndrzej Lisowski
Andrzej Lisowski
DMDorota Mantey
Dorota Mantey
WWWaldemar Wilk
Waldemar Wilk

11 September 2019 in New Zealand Veterinary Journal
Verified
Journal Article
Closed access
ISIrene Sartini
Irene Sartini
BŁBEATA ŁEBKOWSKA-WIERUSZEWSKA
BEATA ŁEBKOWSKA-WIERUSZEWSKA
ALA Lisowski
A Lisowski
APAmnart Poapolathep
Amnart Poapolathep
HOH Owen
H Owen
MVMario Giorgi Dip Scienze Veterinarie
Mario Giorgi Dip Scienze Veterinarie
AIMS: To determine the pharmacokinetics and tissue depletion of 2 mg/kg marbofloxacin (MBX) in Bilgorajska geese (Anser anser domesticus) after I/V and oral administration, to calculate the daily dose from experimental data and to compare it with that calculated by allometric scaling. METHODS: Eight clinically normal female Bilgorajska geese were used in a three-phase study with a 3-week wash-out period between phases. In the first phase birds received I/V administration of 2 mg/kg MBX, the same dose was given orally in the second and third phases. Blood samples were collected between 0 minutes and 48 hours in the first and second phases, and samples of liver, kidney, lung, muscle and heart were collected following slaughter of birds between 6 and 48 hours in the third phase. Concentrations of MBX in plasma and tissues were analysed using HPLC. Two additional birds served as controls. The optimal dose was calculated based on a minimal inhibitory concentration (MIC) of 0.125 μg⁄mL using the observed pharmacokinetic parameters, or using clearance calculated by allometric scaling. RESULTS: Concentrations of MBX in plasma were detectable up to 24 hours following both I/V and oral administration. Mean oral bioavailability was 26.5 (SD 7.7)%. Concentrations of MBX in all tissues were highest at 6 hours and decreased constantly up to 34 hours. The mean optimal daily dose for oral administration of MBX, calculated using the observed clearance was 10.36 (SD 2.18) mg/kg, and using predicted clearance was 5.54 (SD 0.14) mg/kg. The preliminary withdrawal time for a maximum residue limit of 0.15 mg/kg calculated for muscle was 38.4 hours, heart 33.6 hours, kidney 48.3 hours, lung 47.7 hours and liver 49.3 hours. CONCLUSION AND CLINICAL RELEVANCE: There was insufficient evidence to recommend MBX orally administered to geese at a daily dose of 2 mg⁄kg for treatment of bacteria with an MIC of 0.125 μg ⁄mL. Further pharmacokinetic /pharmacodynamic studies in geese are recommended to determine the MBX dose regimen and its clinical efficacy in geese.

28 July 2022 in Journal of Veterinary Pharmacology and Therapeutics
Verified
Journal Article
Open access
CFCharbel Fadel
Charbel Fadel
BŁBEATA ŁEBKOWSKA-WIERUSZEWSKA
BEATA ŁEBKOWSKA-WIERUSZEWSKA
ISIrene Sartini
Irene Sartini
ALAndrzej Lisowski
Andrzej Lisowski
APAmnart Poapolathep
Amnart Poapolathep
MVMario Giorgi Dip Scienze Veterinarie
Mario Giorgi Dip Scienze Veterinarie
The aim of this study was to evaluate the pharmacokinetics (PK) of robenacoxib (RX), a COX‐2 selective non‐steroidal anti‐inflammatory drug, in sheep after single subcutaneous (SC), oral (PO), and intravenous (IV) administration. Five healthy female sheep underwent a three‐phase parallel study design with a washout period of 4 weeks, in which sheep received a 4 mg/kg SC dose in phase 1, a 4 mg/kg PO administration in phase 2, and a 2 mg/kg IV administration in phase 3. Plasma RX concentrations were measured over a 48 h period for each treatment using HPLC coupled to a UV multiple wavelength detector, and the PK parameters were estimated using a non‐compartmental method. Following IV administration, terminal elimination half‐life, volume of distribution at steady state, and total clearance were 2.64 h, 0.077 L/kg, and 0.056 L/h kg, respectively. The mean peak plasma concentrations following SC and PO administrations were 7.04 and 3.01 μg/mL, respectively. The mean bioavailability following SC and PO administrations were 45.98% and 16.58%, respectively. The SC route may be proposed for use in sheep. However, the multi‐dose and pharmacodynamic studies are necessary to establish more accurately its safety and efficacy in sheep.

28 May 2023 in Journal of Veterinary Pharmacology and Therapeutics
Verified
Journal Article
Open access
CFCharbel Fadel
Charbel Fadel
BŁBEATA ŁEBKOWSKA-WIERUSZEWSKA
BEATA ŁEBKOWSKA-WIERUSZEWSKA
CZClaudia Zizzadoro
Claudia Zizzadoro
ALAndrzej Lisowski
Andrzej Lisowski
APAmnart Poapolathep
Amnart Poapolathep
MVMario Giorgi Dip Scienze Veterinarie
Mario Giorgi Dip Scienze Veterinarie
The purpose of this study was to assess the pharmacokinetics of robenacoxib (RX), a COX‐2 selective non‐steroidal anti‐inflammatory drug, in goats after single intravenous (IV), subcutaneous (SC) and oral (PO) administrations. 5‐month‐old healthy female goats (n = 8) were used. The animals were subjected to a three‐phase, two‐dose (2 mg/kg IV, 4 mg/kg SC, PO) unblinded, parallel study design, with a four‐month washout period between the IV and SC treatment, and a one‐week period between the SC and PO treatment. Blood was drawn from the jugular vein in heparinized vacutainer tubes at 0, 0.085 (for IV only), 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 10 and 24 h. Plasma RX concentrations were measured using HPLC coupled to a UV multiple wavelength detector, and the data were pharmacokinetically analysed using ThothPro™ 4.3 software in a non‐compartmental approach. Following IV administration, terminal elimination half‐life, volume of distribution and total clearance were 0.32 h, 0.24 L/kg and 0.52 L/h/kg, respectively. For SC and PO, the mean peak plasma concentrations were 2.34 and 3.34 μg/mL at 1.50 and 0.50 h, respectively. The t1/2λz was significantly different between the IV and the extravascular (EV) administrations (0.32 h IV vs 1.37 h SC and 1.63 h PO), suggesting the occurrence of a flip‐flop phenomenon. The significant difference in Vd values between IV (0.24 L/kg) and EV (0.95 L/kg SC and 1.71 L/kg; corrected for F %) routes might have also triggered the t1/2λz difference. The absolute average SC and PO bioavailability were high (98% and 91%, respectively). In conclusion, the IV administration of RX might not be suitable for goats, due to its short t1/2λz. The EV routes, however, appear to be convenient for the drug's occasional use.

27 July 2021 in Journal of Veterinary Pharmacology and Therapeutics
Verified
Journal Article
Open access
PDF file
ISIrene Sartini
Irene Sartini
BŁBEATA ŁEBKOWSKA-WIERUSZEWSKA
BEATA ŁEBKOWSKA-WIERUSZEWSKA
ALAndrzej Lisowski
Andrzej Lisowski
APAmnart Poapolathep
Amnart Poapolathep
ASAndrejs Sitovs
Andrejs Sitovs
MVMario Giorgi Dip Scienze Veterinarie
Mario Giorgi Dip Scienze Veterinarie
The study aims to describe the pharmacokinetics of doxycycline after a single intravenous and oral dose (20 mg/kg) in geese. In addition, two multiple‐dose simulations have been performed to investigate the predicted plasma concentration after either a 10 or 20 mg/kg daily administration repeated consecutively for 5 days. Ten geese were enrolled in a two‐phase cross‐over study with a washout period of two weeks. All animals were treated intravenously and orally with doxycycline, and blood samples were collected up to 48 h after drug administration. Sample analysis was performed using a validated HPLC‐UV method. A non‐compartmental approach was used to evaluate the pharmacokinetic parameters of the drug. A long elimination half‐life was observed (13 h). The area under the curve was statistically different between the two treatments, with the oral bioavailability being moderate (43%). The pharmacokinetic/pharmacodynamic index (%T>MIC) during the 48 h treatment period in the present study (71%) suggests that doxycycline appears to have therapeutic efficacy against some Mycoplasma species in the goose. The multiple‐dose simulations showed a low accumulation index. A dosage of 10 mg/kg/day for 5 days seemed to be adequate for a good therapeutic efficacy without reaching unnecessarily high plasma concentrations.